Xenon Pharmaceuticals Inc

NASDAQ:XENE  
18.62
-0.38 (-2.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)746.75M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.76 Million
Adjusted EPS-$0.48
See more estimates
10-Day MA$18.90
50-Day MA$18.48
200-Day MA$14.95
See more pivots

Xenon Pharmaceuticals Inc Stock, NASDAQ:XENE

3650 Gilmore Way, Suite 200, Burnaby, British Columbia V5G 4W8
Canada
Phone: +1.604.484.3300
Number of Employees: 129

Description

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.